ArticleDiscover oncology2025
Unveiling novel susceptibility genes and drug targets for basal cell carcinoma by a cross-tissue transcriptome-wide association study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo identify novel susceptibility genes and drug targets for basal cell carcinoma (BCC).
methodsWe performed a transcriptome-wide association study (TWAS) to identified the susceptibility genes and potential drug targets for BCC. The cross-tissue TWAS was conducted to discover the candidate genes for BCC. Functional Summary-based Imputation (FUSION) analysis was used to validate these genes in the single tissues. Multimarker Analysis of Genomic Annotation (MAGMA) was employed to further screen candidate genes. Summary data-based Mendelian randomization (SMR) and colocalization analyses were applied to infer causal relationships between candidate genes and BCC. The expression pattern of the identified genes in single-cell types was also investigated. Function, pathway enrichment and disease connection analyses were performed to understand the biological implication of identified genes. Additionally, druggability of the identified genes was evaluated to discover potential candidate drugs for BCC.
resultsNinety-five genes were identified by cross-tissue TWAS analysis. Among them, 24 genes were confirmed by FUSION and MAGMA methods. Ten genes were further confirmed by SMR and colocalization analyses. Three genes were replicated by using another GWAS data. The potential interacting gene networks constructed with these identified genes were mainly involved in viral life cycle-HIV-1, GABAergic synapse, nicotine addiction, ether lipid metabolism, and mineral absorption pathways. AN-9 and amooranin might be candidate drugs for BCC.
conclusionsWe have identified 10 susceptibility genes associated with BCC risk, which might deepen our comprehension of BCC pathogenesis and illuminating new avenues for therapeutic and preventive drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.